Seeking Alpha
12 Jun 2026, 16:43 UTC · 3h ago
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
12 Jun 2026, 16:43 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Recursion Pharmaceuticals expects an update on the anti-tumor activity of REC-1245 from the DHALIA trial in H2 2026. — Confirmation of efficacy in solid tumors would be a primary value driver for the company's pipeline.
+0.50No dose-limiting toxicities have been observed for REC-1245 in the DHALIA trial to date. — Safety data reduces the risk of early-stage clinical failure, though it does not prove efficacy.
+0.30Initial DHALIA trial data are limited due to a small cohort of 16 patients and the drug only recently reaching active dose levels. — The lack of immediate, conclusive data delays the catalyst for a positive price movement.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is reporting no dose-limiting toxicities in its REC-1245 trial, though data is currently limited.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
6h ago
